X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA AUROBINDO PHARMA PLETHICO PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x -1.1 14.2 - View Chart
P/BV x 0.0 3.7 0.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PLETHICO PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
AUROBINDO PHARMA
Mar-17
PLETHICO PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs395895 44.1%   
Low Rs31622 5.0%   
Sales per share (Unadj.) Rs604.4254.6 237.4%  
Earnings per share (Unadj.) Rs32.539.3 82.7%  
Cash flow per share (Unadj.) Rs51.346.6 110.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs473.6160.0 296.0%  
Shares outstanding (eoy) m34.08585.88 5.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.43.0 11.8%   
Avg P/E ratio x6.619.3 34.0%  
P/CF ratio (eoy) x4.216.3 25.5%  
Price / Book Value ratio x0.54.7 9.5%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m7,262444,390 1.6%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m1,59617,678 9.0%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m20,598149,157 13.8%  
Other income Rs m3861,159 33.3%   
Total revenues Rs m20,984150,316 14.0%   
Gross profit Rs m2,81834,343 8.2%  
Depreciation Rs m6424,276 15.0%   
Interest Rs m1,593667 238.8%   
Profit before tax Rs m96930,558 3.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1387,597 -1.8%   
Profit after tax Rs m1,10723,012 4.8%  
Gross profit margin %13.723.0 59.4%  
Effective tax rate %-14.324.9 -57.5%   
Net profit margin %5.415.4 34.8%  
BALANCE SHEET DATA
Current assets Rs m18,87792,062 20.5%   
Current liabilities Rs m11,89666,223 18.0%   
Net working cap to sales %33.917.3 195.6%  
Current ratio x1.61.4 114.1%  
Inventory Days Days36106 33.9%  
Debtors Days Days19868 292.3%  
Net fixed assets Rs m9,86162,919 15.7%   
Share capital Rs m341586 58.1%   
"Free" reserves Rs m12,33193,133 13.2%   
Net worth Rs m16,13993,719 17.2%   
Long term debt Rs m4,7061,814 259.4%   
Total assets Rs m33,146162,494 20.4%  
Interest coverage x1.646.8 3.4%   
Debt to equity ratio x0.30 1,506.5%  
Sales to assets ratio x0.60.9 67.7%   
Return on assets %8.114.6 55.9%  
Return on equity %6.924.6 27.9%  
Return on capital %12.332.7 37.5%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40275,838 5.8%   
Fx outflow Rs m3,18430,224 10.5%   
Net fx Rs m1,21945,613 2.7%   
CASH FLOW
From Operations Rs m2,43732,786 7.4%  
From Investments Rs m-6,265-17,870 35.1%  
From Financial Activity Rs m2,490-19,153 -13.0%  
Net Cashflow Rs m-1,337-4,239 31.5%  

Share Holding

Indian Promoters % 82.7 54.1 152.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 8.0 54.1%  
FIIs % 5.5 27.7 19.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.2 73.5%  
Shareholders   10,665 69,601 15.3%  
Pledged promoter(s) holding % 85.7 8.6 1,001.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS